Posted by Michael Wonder on 05 Mar 2024
Sandoz receives FDA approval for first and only denosumab biosimilars
5 March 2024 - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva (denosumab) and Prolia (denosumab).
Sandoz today announced that the US FDA approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA approved denosumab biosimilars, to treat all indications of the reference medicines.
